COMMUNIQUÉS West-GlobeNewswire

Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
29/09/2026
Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 data Topline results expected in the first [...]
Apyx Medical Announces New Clinical Study Demonstrating Renuvion®’s Impact on Skin Quality
29/09/2026
Patients reported high satisfaction and visible improvements in skin elasticity, youthfulness, and radiance CLEARWATER, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or [...]
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
29/09/2026
- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms- - The study will evaluate changes in blood- [...]
DiFusion to Define Therapeutic Biomaterials Category at NASS 2026
29/09/2026
Red Theater presentation will distinguish conventional biotolerable implants from materials deliberately engineered to influence the host response and participate in healing AUSTIN, Texas, Sept. 29, 2026 (GLOBE NEWSWIRE [...]
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
29/09/2026
New data show deepening improvement in ocular MG and sustained one-year efficacy in anti-AChR antibody-negative MG – broadening VYVGART's potential to treat all MG patients Real-world evidence from more than 1,100 U.S. [...]
Glass House Brands Announces Planned Retirement of Chief Financial Officer
29/09/2026
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated June 10, 2026, to its short form base shelf prospectus dated June 10, 2026. LONG BEACH, Calif. and [...]
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB
29/09/2026
October 20th Meeting with the Division of Neurology Expected to Define Endpoint for Phase 3 PURCHASE, N.Y., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the Company or Cognition) (NASDAQ: CGTX), a [...]
Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis
29/09/2026
Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retreatment; mean MG-ADL reduction of 6.6 points at Month 12 following retreatment Median interval between end [...]
Optimi Health Appoints Melanie Pump to Board of Directors
29/09/2026
Seasoned finance executive brings more than 25 years of leadership experience across technology, digital infrastructure, software, fintech and emerging growth companies VANCOUVER, British Columbia, Sept. 29, 2026 (GLOBE [...]
Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
29/09/2026
Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company’s capital-efficient development strategy PHILADELPHIA, Sept. 29 [...]
Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
29/09/2026
Demonstrated Major Response Rate of 79.2%, Overall Response Rate of 87.5%, and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Data [...]
uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression
29/09/2026
~ In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent response; the primary endpoint of cUHDRS showed 44% slowing of [...]
Kraig Biocraft Laboratories Ships its First Commercial Spider Silk Yarn Order for Performance Sports Brand
29/09/2026
Milestone Marks Recombinant Spider Silk’s Move from Scaled Production to a First-of-Its-Kind Performance Textile ANN ARBOR, Mich., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the [...]
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
29/09/2026
LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an [...]
Boehringer Ingelheim investments into sustainability-related programs and health partnerships to reach EUR 500 million
29/09/2026
Company investments from the past five years, together with the forecast for 2026, are projected to reach EUR 500 million by year-end 2026, encompassing all expenditure on sustainability-related projects and health [...]
Ocugen to Participate in Upcoming October Investor and Industry Conferences
29/09/2026
MALVERN, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that members of [...]
PolarityBio’s Phase 3 COVER DFUS II Trial Selected for First-to-Podium Presentation at SAWC Fall 2026
29/09/2026
Pivotal SkinTE® data in non-healing Wagner Grade 1 diabetic foot ulcers to be presented by Study Chair Robert S. Kirsner, MD, PhD, on October 16 SALT LAKE CITY, Sept. 29, 2026 (GLOBE NEWSWIRE) -- PolarityBio® , a late- [...]
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
29/09/2026
VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the safety and [...]
BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis
29/09/2026
FDA Fast Track designation represents an important regulatory milestone for the Plinabulin and docetaxel combination as an anticancer regimen in 2L/3L advanced or metastatic non-squamous NSCLC without actionable genomic [...]

Pages